Cargando…

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease

INTRODUCTION: Parkinson’s therapeutic interventions are only symptomatic. An optimal treatment should therefore address the largest number of motor and non-motor symptoms, to manage patients at best. Safinamide is one of the most recent approved drugs for fluctuating patients, in add-on to levodopa,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbruzzese, Giovanni, Barone, Paolo, Lopiano, Leonardo, Stocchi, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203199/ https://www.ncbi.nlm.nih.gov/pubmed/34140766 http://dx.doi.org/10.2147/DDDT.S302673

Ejemplares similares

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
por: Bette, Sagari, et al.
Publicado: (2018)

The effects of safinamide on dysphagia in Parkinson’s disease
por: Hirano, Makito, et al.
Publicado: (2023)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
por: Antonini, Angelo, et al.
Publicado: (2008)

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
por: Gómez-López, Ana, et al.
Publicado: (2021)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Overall Efficacy and Safety of Safinamide in Parkinson’s Disease: A Systematic Review and a Meta-analysis
por: Giossi, Riccardo, et al.
Publicado: (2021)

A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease
por: Abdelalem Aziz Ahmed, Mohamed
Publicado: (2019)

Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021)

Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

The “Gender Factor” in Wearing-Off among Patients with Parkinson's Disease: A Post Hoc Analysis of DEEP Study
por: Colombo, Delia, et al.
Publicado: (2015)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021)

Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients
por: Cattaneo, Carlo, et al.
Publicado: (2020)

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial(1)
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
por: Labandeira, Carmen M., et al.
Publicado: (2021)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
por: Peña, Esteban, et al.
Publicado: (2021)

Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2015)

How to optimize the treatment of early stage Parkinson’s disease
por: Stocchi, Fabrizio, et al.
Publicado: (2015)

Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study
por: De Micco, Rosa, et al.
Publicado: (2021)

Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
por: De Masi, Claudia, et al.
Publicado: (2022)

The effects of safinamide according to gender in Chinese parkinsonian patients
por: Pellecchia, M. T., et al.
Publicado: (2023)

Safety and efficacy of tolcapone in Parkinson’s disease: systematic review
por: Artusi, Carlo Alberto, et al.
Publicado: (2021)

Deep Brain Stimulation Selection Criteria for Parkinson’s Disease: Time to Go beyond CAPSIT-PD
por: Artusi, Carlo Alberto, et al.
Publicado: (2020)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
por: Bergmans, Bruno, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_475s5hu39ddl99gqj0m0eiv2vg